替吉奥维持治疗一线化疗后无疾病进展晚期胃癌的PSM分析  

PSM Analysis of Advanced Gastric Cancer without Disease Progression after First-Line Chemotherapy with Teggio Maintenance Therapy

作　　者：陆元元 丁文评 LU Yuanyuan;DING Wenping(The First Affiliated Hospital of Wannan Medical College&Yijishan Hospital,Wuhu,Anhui Province 241001,China)

机构地区：[1]皖南医学院第一附属医院/弋矶山医院,安徽芜湖241001

出　　处：《吉林医药学院学报》2025年第1期33-37,共5页Journal of Jilin Medical University

基　　金：安徽省教育厅科学研究项目(KJ2021A0827)。

摘　　要：目的通过倾向性评分匹配(propensity score matching,PSM)分析替吉奥维持治疗一线化疗后无疾病进展晚期胃癌的疗效和安全性。方法选取2021年1月到2022年12月收治的晚期胃癌患者,采用PSM最临近匹配法以1∶1的比例选取替吉奥组(化疗周期结束后替吉奥维持治疗)和对照组(化疗周期结束后随访观察)患者各44例。比较两组临床疗效、无进展生存期(progression-free survival,PFS)、肿瘤标志物及不良反应情况。结果随访截止至2024年3月20日,中位随访时间22.9个月,替吉奥组中位PFS为11.5个月(95%CI:10.961~12.039),对照组中位PFS为8.3个月(95%CI:8.011~8.589),替吉奥组PFS高于对照组(χ^(2)=10.125,P=0.001)。3个月随访时替吉奥组癌胚抗原、糖类抗原199、糖类抗原125和糖类抗原724水平低于基线时和对照组。随访期间替吉奥组血小板减少和手足综合征比例高于对照组,不良事件均通过症状治疗或减少替吉奥剂量得到了有效控制和缓解。结论替吉奥维持治疗一线化疗后无疾病进展晚期胃癌可抑制肿瘤侵袭,延长患者PFS,治疗期间应注意观察患者不良反应,及时对症处理。Objective To analyze the efficacy and safety of Teggio maintenance in the treatment of advanced gastric cancer without dis‐ease progression after first-line chemotherapy by propensity score matching(PSM).MethodsPatients with advanced gastric cancer ad‐mitted from January 2021 to December 2022 were selected.PSM nearest matching method was used to select 44 patients in each group(maintenance treatment after chemotherapy cycle)and control group(follow-up observation after chemotherapy cycle)with a ratio of 1∶1.The clinical efficacy,progression-free survival(PFS),tumor markers and adverse reactions were compared between the two groups.ResultsThe median follow-up time was 22.9 months as of March 20,2024.The median PFS of the Teggio group was 11.5 months(95%CI:10.961~12.039)and that of the control group was 8.3 months(95%CI:8.011~8.589),the PFS in the Teggio group was higher than that in the control group(χ^(2)=10.125,P=0.001).At 3-month follow-up,the levels of CEA,CA199,CA125,and CA724 in the Tegio group were lower than at baseline and in the control group.The proportion of thrombocytopenia and hand-foot syndrome in the Teggio group was higher than that in the control group during follow-up,and adverse events were effectively controlled and alleviated by symptom treatment or dose reduction of Teggio.ConclusionTeggio maintenance therapy can inhibit tumor invasion and prolong the progression-free survival of patients with advanced gastric cancer after first-line chemotherapy.During treatment,attention should be paid to the adverse reactions of patients and timely symptomatic treatment.

关 键 词：胃癌 维持治疗 无进展生存期 替吉奥 化疗 

分 类 号：R735.2[医药卫生—肿瘤]